冠状病毒小分子抑制剂研究进展  

Research progress on small molecule inhibitors of coronaviruses

作　　者：姚争光 王志斌 夏春年[1] 庄春林 YAO Zhengguang;WANG Zhibin;XIA Chunnian;ZHUANG Chunlin(School of Pharmacy,Zhejiang University of Technology,Hangzhou 310014,China;School of Pharmacy,Naval Medical University,Shanghai 200433,China)

机构地区：[1]浙江工业大学药学院,浙江杭州310014 [2]海军军医大学药学院,上海200433

出　　处：《药学实践杂志》2020年第5期385-397,共13页Journal of Pharmaceutical Practice

基　　金：中国科协青年人才托举工程(2017QNRC061)。

摘　　要：冠状病毒感染严重威胁着人类健康,目前尚无特异性治疗药物或疫苗。近年来,针对SARS-CoV、MERSCoV、SARS-CoV-2这3种高致病性冠状病毒的配体S蛋白、RdRp、PLpro和3CLpro等靶点,国内外研究者已经开发了多种小分子抑制剂。综述这些冠状病毒的特点、作用靶点、小分子抑制剂及其构效关系。Coronavirus infection seriously threatens human health.There is no specific medication or vaccine so far.In recent years,domestic and foreign researchers have developed a variety of small-molecule inhibitors against the ligand S protein,RdRp,PLpro and 3CLpro of three highly pathogenic coronavirus,SARS-CoV,MERS-CoV,SARS-CoV-2.This article reviews the characteristics of these coronaviruses,action targets,small molecule inhibitors,and structure-activity relationships.

关 键 词：冠状病毒 严重急性呼吸系统综合征冠状病毒 中东呼吸综合征冠状病毒 新型冠状病毒 靶点 抑制剂 

分 类 号：R373[医药卫生—病原生物学]